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ABSTRACT  
BACKGROUND 
The leading cause of death for patients suffering from type 2 diabetes is macrovascular disease. 
Endothelial dysfunction is one of the earliest events identified in the pathogenesis of 
atherosclerosis. Hence, there is a need for finding glucose-lowering agents that cause direct 
positive effects on vasculature in diabetic patients. The aim of this work was to evaluate the 
putative role and potential effects of incretins i.e. GLP-1 and exendin-4 on the vasculature and to 
elucidate the mechanisms behind these effects.   
STUDY I 
We investigated whether incretins influence proliferation of human coronary artery endothelial 
cells (HCAECs) in vitro and studied the molecular mechanisms behind such effects. Exendin-4, 
GLP-1 (7-36) and GLP-1 (9-36) elicited dose-dependent increases in DNA synthesis and 
increased cell number. This mitogenic effect was associated with increased eNOS and Akt 
activity, which along with the augmented cell proliferation were blocked by PKA-, PI3K-, Akt- 
and eNOS-inhibitors and by a GLP-1 receptor antagonist, exendin (9-39).  
STUDY II 
We studied the role of exendin-4 on apoptosis of HCAECs under lipotoxic conditions in vitro. 
Palmitate provoked apoptosis, an effect that was inhibited by exendin-4 or GLP-1 (7-36). In 
contrast, palmitate-induced apoptosis was not affected by GLP-1 (9-36). Palmitate alone resulted 
in increased eNOS, p-38 MAPK and JNK phosphorylation, which were neutralized by exendin-
4. The protective effect of exendin-4 on apoptosis was prevented after treatment of the cells with 
specific inhibitors for PKA, PI3K, eNOS, p38 MAPK or for JNK. The effect of exendin-4 on 
lipoapoptosis was blocked by the GLP-1 receptor antagonist, exendin (9-39). 
STUDY III 
In this study, we investigated the long-term in vitro effect of palmitate or high glucose, and the 
role of exendin-4, on gene expression in HCAECs. Our data show that the expression of eNOS 
was up-regulated by exendin-4 in the presence of either palmitate or high glucose, as 
demonstrated by both microarray and Western blotting analyses. However, microarray analysis 
showed a suppressed eNOS expression by palmitate, which was not observed in Western blot. 
The expression of tyrosine kinase receptor Tie-2 and its ligand Ang-1 was up-regulated in the 
presence of exendin-4. Moreover, exendin-4 increased the expression of tissue plasminogen 
activator (TPA) and cell adhesion molecules involved in angiogenesis, such as platelet 
endothelial cell adhesion molecule (PECAM), cadherin-5 and extracellular matrix protein 
fibronectin. Angiotensin І-converting enzyme (ACE) expression was up-regulated by high 
glucose, whereas exendin-4 inhibited expression of this gene at high glucose.  
STUDY IV 
The aim of this study was to investigate whether exendin-4 could protect against endothelial 
dysfunction induced by a triglyceride-rich fat emulsion, and if there were any differences in 
vasorelaxant capacity between GLP-1 (7-36), GLP-1 (9-36) and exendin-4 in rat femoral arterial 
rings from non-diabetic rats ex vivo. Exendin-4 did not protect against lipotoxicity, whereas 
GLP-1 (7-36) and GLP-1 (9-36) exerted vasorelaxation. 
CONCLUSIONS 
GLP-1 receptor agonists stimulate the proliferation of HCAECs, protect them from 
lipoapoptosis and improve endothelial function in part through regulating expression of genes 
involved in angiogenesis, inflammation and thrombogenesis by reversing glucolipotoxic gene 
regulation. Improvement of endothelial dysfunction may translate into beneficial effects on 
many cardiovascular risk factors and may thus have important clinical implications in 
preventing and treating macroangiopathy in type 2 diabetes. 
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